VCNX News and Press, Vaccinex Inc. From 05/14/20

Vaccinex (NASDAQ: VCNX ): Q1 GAAP EPS of -$0.45 beats by $0.30 . More news on: Vaccinex, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to expand pepinemab development to include Alzheimer’s disease ROCHESTER, N.Y., May 14, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotech...

ROCHESTER, N.Y., May 13, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced a poster presentation highlighting ...

Every solution to every problem is simple. It's the distance between the two where the mystery lies . - Derek Landy Today, we take an in-depth look at a ‘ Tier 4 ’ biotech concern located in upstate New York. The concern posted some updated trial results this morning that ...

Thinly traded nano cap Vaccinex ( VCNX +9.8% ) is up more than an 8x surge in volume, albeit on turnover of only 289K shares, on the heels of updated data from a Phase 1b/2 clinical trial, CLASSICAL-Lung , evaluating pepinemab, combined with Pfizer ( PFE +1.5% ) and Merck KGaA's ( OTC...

Vaccinex (NASDAQ: VCNX ) presents updated interim results from CLASSICAL-Lung, the Phase 1b/2 study of pepinemab in combination with anti-PD-L1 checkpoint inhibitor avelumab (BAVENCIO) in non-small cell lung cancer (NSCLC), at the American Association for Cancer Research. More news on: V...

ROCHESTER, N.Y., April 27, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), today announced the presentation ...

ROCHESTER, N.Y., April 07, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases, today announced that the company’s vice president of preclinical res...

Kiniksa Pharmaceuticals (NASDAQ: KNSA ) announces "early evidence" of treatment response in COVID-19-related pneumonia and hyperinflammation with antibody mavrilimumab. Shares up  42%  premarket. More news on: Kiniksa Pharmaceuticals, Ltd., Vaccinex, Inc., BioCorRx Inc., Health...

ROCHESTER, N.Y., March 31, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative diseases, today announced that the company has entered into two agreements that combi...